BioCentury
ARTICLE | Deals

New deal strategy gives AbCellera more upside without straying from its roots

Tachyon, EQRx deals give AbCellera options to invest in development, gaining more royalties, ownership of assets

August 4, 2021 11:42 PM UTC

Via its deals with EQRx and Tachyon, AbCellera has unveiled a new partnership strategy that could provide the biotech with more upside without straying from its discovery-focused business model.

On Wednesday, AbCellera Biologics Inc. (NASDAQ:ABCL) partnered with EQRx Inc. to discover and develop multiple undisclosed mAbs spanning therapeutic areas, with an initial focus on targets in oncology and immunology. ...